Not provided
Not provided
Not provided
Not provided
Safety issues in the LDFD-group (higher heart rate with dopamine)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to compare the effects of 1) high-dose furosemide, 2) low-dose furosemide, and 3) low-dose furosemide combined with low-dose dopamine on diuresis, clinical status, renal function, electrolyte balance, length of stay, and 60-day post-discharge outcomes in patients hospitalized with acute decompensated heart failure.
The aim of this study is to compare the effects of:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| High-dose furosemide | Active Comparator | High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours |
|
| Low-dose furosemide | Active Comparator | Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide |
|
| Low-dose furosemide combined with low-dose dopamine | Active Comparator | Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| High-dose furosemide | Drug | High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours |
|
| Measure | Description | Time Frame |
|---|---|---|
| 1-year mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure). | 1-year |
| Measure | Description | Time Frame |
|---|---|---|
| 60-day mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure). | 60-day post discharge | |
| Novel indices of acute renal ischemia/injury (cystatin-C, KIM-1, NGAL) | Throughout hospitalization |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gregory Giamouzis, MD | Department of Cardiology, Larissa University Hospital, Larissa, Greece | Study Chair |
| Filippos Triposkiadis, MD | Department of Cardiology, Larissa University Hospital, Larissa, Greece | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Division of Cardiology, Emory University Hospital | Atlanta | Georgia | United States | |||
| The Cleveland Clinic Foundation |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24485633 | Derived | Triposkiadis FK, Butler J, Karayannis G, Starling RC, Filippatos G, Wolski K, Parissis J, Parisis C, Rovithis D, Koutrakis K, Skoularigis J, Antoniou CK, Chrysohoou C, Pitsavos C, Stefanadis C, Nastas J, Tsaknakis T, Mantziari L, Giannakoulas G, Karvounis H, Kalogeropoulos AP, Giamouzis G. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. Int J Cardiol. 2014 Mar 1;172(1):115-21. doi: 10.1016/j.ijcard.2013.12.276. Epub 2014 Jan 10. |
Not provided
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| D007008 | Hypokalemia |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014883 | Water-Electrolyte Imbalance |
| D008659 | Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D005665 | Furosemide |
| D004298 | Dopamine |
| ID | Term |
|---|---|
| D013424 | Sulfanilamides |
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Low-dose furosemide | Drug | Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide |
|
| Low-dose furosemide combined with low-dose dopamine | Drug | Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours |
|
| Cleveland |
| Ohio |
| United States |
| First Department of Cardiology, University of Athens | Athens | Attica | Greece |
| Department of Cardiology, Larissa University Hospital | Larissa | Larissa | 411 10 | Greece |
| Department of Cardiology, Volos General Hospital | Volos | Magnesia | 382 21 | Greece |
| AHEPA University Hospital | Thessaloniki | Thessaloniki | Greece |
| D009750 |
| Nutritional and Metabolic Diseases |
| D000814 |
| Aniline Compounds |
| D000588 | Amines |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D015306 | Biogenic Monoamines |
| D001679 | Biogenic Amines |
| D002395 | Catecholamines |
| D002396 | Catechols |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |